Clinical observation of auxiliary function of anti-inflammatory Chinese herbal medicine in chemotherapy of middle and advanced lung cancer

Hubei Cancer Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. The patients voluntarily joined the study, signed the informed consent form, and had good compliance.
•2. Patients diagnosed with lung cancer according to imaging, cytology and histological examinations; patients diagnosed with lung cancer in stages IIIB-IV according to the 8th edition of the International Union Against Cancer (UICC) revised TNM staging.
•3. Patients who are or will be receiving platinum-based chemotherapy.
•4. Estimated survival > 3 months.
•5. KPS score > 60 points.
•6. Aged >= 18 years.

•1. Those with other active malignant tumors or those who have not recovered from other major operations before;
•2. There are factors that obviously affect the absorption of oral drugs, such as inability to swallow, chronic diarrhea and intestinal obstruction;
•3. Complicated with severe infection or confirmed to have other major physiological dysfunction;
•4. Patients with serious diseases such as the heart, liver, kidney, hematopoietic system, as well as those with severe functional impairment, and mentally ill patients;
•5. Pregnant and lactating patients;
•6. Those who cannot cooperate with the treatment;
•7. Allergic constitution, history of allergy to chrysanthemum, licorice, or history of severe food or drug allergy.

发起方

Hubei Cancer Hospital